注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Repligen Corp是一家生命科学公司,致力于开发生物加工技术和系统并将其商业化,从而提高生物药物制造过程的灵活性。该公司的生物加工业务包括四个特许经营权,过滤;色谱法;过程分析;和蛋白质。过滤产品用于工艺开发和工艺规模(临床和商业)生产。色谱特许经营权包括用于生物药物下游纯化、开发和制造的产品。过程分析产品允许终端用户进行在线吸光度测量,从而确定过滤、色谱配方和填充完成应用中的蛋白质浓度。蛋白质特许经营权以蛋白A亲和配体为代表,这是用于市场上几乎所有基于单克隆抗体(mAb)药物的下游纯化的蛋白A层析树脂的关键组成部分。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Glenn P. Muir | 62 | 2015 | Independent Director |
Nicholas M. Barthelemy | 55 | 2014 | Independent Director |
Karen A. Dawes | 70 | 2005 | Independent Chairperson of the Board |
Steven M. Cramer | - | 2016 | Member of Scientific Advisory Board |
Konstantin Konstantinov | 65 | 2016 | Member of Scientific Advisory Board & Independent Director |
Richard D. Braatz | - | - | Member of Scientific Advisory Board |
Martin D. Madaus | 63 | 2023 | Independent Director |
J. Christopher Love | - | 2016 | Member of Scientific Advisory Board |
Carrie Eglinton Manner | 48 | 2020 | Independent Director |
Charles Leland Cooney | 79 | 2016 | Member of Scientific Advisory Board |
Rohin Mhatre | 58 | 2020 | Independent Director |
Anthony J. Hunt | 59 | 2014 | CEO & Director |
Hubert A. Scoble | - | 2024 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核